From the Research
Cagrisema is typically dosed at 2.4 mg subcutaneously once weekly for adults with obesity or overweight with weight-related comorbidities, as supported by the most recent and highest quality study 1.
Key Considerations
- Treatment should be initiated at a lower dose of 0.6 mg weekly for the first month, then increased to 1.2 mg weekly for the second month, followed by 1.8 mg weekly for the third month, before reaching the maintenance dose of 2.4 mg weekly.
- This gradual titration helps minimize gastrointestinal side effects such as nausea, vomiting, and diarrhea.
- Patients should inject the medication on the same day each week, and can administer it in the abdomen, thigh, or upper arm.
- The medication should be stored in the refrigerator and brought to room temperature before injection.
- If a dose is missed, patients should administer it as soon as possible within 3 days, then resume their regular schedule.
Mechanism of Action
- Cagrisema works by mimicking GLP-1 and amylin hormones to reduce appetite, slow gastric emptying, and promote satiety, leading to reduced caloric intake and weight loss.
Supporting Evidence
- A multicentre, randomised, double-blind, active-controlled, phase 2 trial found that co-administered semaglutide with cagrilintide (CagriSema) resulted in clinically relevant improvements in glycaemic control and significant weight loss compared to semaglutide and cagrilintide alone 1.
- Other studies have shown that GLP-1 receptor agonists, such as semaglutide, have beneficial effects on cardiovascular outcomes and mortality in patients with type 2 diabetes 2, 3, 4.
- A systematic review and meta-analysis of 21 randomized controlled trials found that dulaglutide, a long-acting GLP-1 receptor agonist, was effective in reducing HbA1c and had a lower risk of hypoglycemia compared to control 5.